Increased FDA transparency on OTC drugs and supply chain
This Act mandates greater transparency from the Food and Drug Administration (FDA) regarding over-the-counter (OTC) monograph drugs. It requires the FDA to publish detailed annual reports on progress in meeting goals regarding OTC monograph order requests and post-market safety activities. Furthermore, the law ensures public access to minutes from negotiation meetings between the FDA and the industry and mandates a report assessing the supply chain of these drugs.
Key points
Progress Reporting: The FDA must publish annual reports including data on the number of OTC monograph orders issued and the average timeline for processing requests.
Drug Safety Monitoring: Reports will include information on FDA's post-market safety activities for OTC drugs, including the collection of adverse event information.
Public Negotiation Minutes: The FDA must make robust written minutes of negotiation meetings with the regulated industry publicly available within 30 days.
Supply Chain Assessment: The Comptroller General will submit a report assessing the stability of the OTC monograph drug supply chain and coordination to mitigate disruptions.
Status:
Introduced
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.